Results 71 to 80 of about 19,263 (243)

Monoclonal antibodies applied in treatment for hematological malignancies [PDF]

, 2018
Monoklonska protutijela su protutijela monovalentnog afiniteta (vežu isti epitop) nastala iz klonova jedinstvene roditeljske B-stanice. Otkriće tehnologije hibirdoma stanica omogućilo je dobivanje mišjih monoklonskih protutijela na željeni antigen, a ...
Lugar, Marija
core   +2 more sources

Analysis of a compartmental model of endogenous immunoglobulin G metabolism with application to multiple myeloma [PDF]

, 2017
Immunoglobulin G (IgG) metabolism has received much attention in the literature for two reasons: (i) IgG homeostasis is regulated by the neonatal Fc receptor (FcRn), by a pH-dependent and saturable recycling process, which presents an interesting ...
Arnulf, Bertrand, Avet-Loiseau, Hervé, Chappell, Michael J., Decaux, Olivier, Dejoie, Thomas, Evans, Neil D., Fouquet, Guillemette, Guidez, Stéphanie, Harding, Stephen, Harel, Stéphanie, Hebraud, Benjamin, Javaugue, Vincent, Kendrick, Felicity, Leleu, Xavier, Moreau, Philippe, Richez, Valentine, Schraen, Susanna, Touzeau, Cyrille   +17 more
core   +2 more sources

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro

Brain, Behavior, & Immunity - Health
Multiple myeloma is a haematological cancer characterised by the accumulation of clonal plasma cells in the bone marrow and is commonly treated with daratumumab, an anti-CD38 monoclonal antibody immunotherapy.
Harrison D. Collier-Bain, Annabelle Emery, Frankie F. Brown, Adam J. Causer, Rebecca Oliver, Rachel Eddy, Shoji Leach, John Graby, Daniel Augustine, Sally Moore, Josephine Crowe, James Murray, James E. Turner, John P. Campbell   +13 more
doaj   +1 more source

Nuevos usos de la talidomida: Del desastre a la esperanza [PDF]

, 2017
Trabajo fin de grado en EnfermeríaLa talidomida se mantiene como uno de los medicamentos más controvertidos históricamente debido a que provocó a nivel mundial numerosos casos de embriopatías en los niños durante la década de los 60.
Williams Aguirre, Ana
core  

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

OncoImmunology, 2019
Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells.
Maria C. Ochoa, Elisabeth Perez-Ruiz, Luna Minute, Carmen Oñate, Guiomar Perez, Inmaculada Rodriguez, Aintzane Zabaleta, Diego Alignani, Myriam Fernandez-Sendin, Ascension Lopez, Aura Muntasell, Miguel F. Sanmamed, Bruno Paiva, Miguel Lopez-Botet, Pedro Berraondo, Ignacio Melero   +15 more
doaj   +1 more source

Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody

Asian Journal of Transfusion Science, 2017
Daratumumab is a monoclonal immunoglobulin against CD38 and has been approved for treating patients with refractory multiple myeloma. The presence of daratumumab in the sera can interfere with pretransfusion testing due to the weakly expression of CD38 ...
Mei-Hwa Lin, Fei-Yun Liu, Hsiu-Mien Wang, Hsin-Ching Cho, Shyh-Chyi Lo   +4 more
doaj   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

Resultados en salud en el tratamiento del mieloma múltiple [PDF]

, 2019
Introducción: El mieloma múltiple es una neoplasia caracterizada por la proliferación incontrolada de células plasmáticas. Es necesario realizar un análisis retrospectivo para evaluar la efectividad de los tratamientos administrados ...
Aguado Paredes, Alicia
core